|
|
 |
|
 |
| MHC Biologics offers breakthrough therapeutic antibody technology targeting a new class of disease biomarkers – peptides presented by the Major Histocompatibility Complex (MHC; also known as human leukocyte antigen, or HLA). These peptides are derived from intracellular processing of tumor or viral proteins and are presented as complexes with MHC proteins on antigen-presenting cells. MHC Biologics’ unique antibody strategy exhibits disease-specific binding and efficacy in preclinical studies as a cancer therapeutic modality, providing next-generation products for treatment of cancer and other important diseases. |
|
 |
|
|
 |
|
 |
